semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-18.0,  Asthma Exacerbation age : 6-18 years suffering from asthma asthma exacerbation during 1/9/2009-15/10/2009 -  any chronic condition that can involve respiratory tract (other than asthma) treated as prevention with ICS or montelukast from July 2010 Treated with oral steroids during the August 2010 asthma exacerbation one week prior study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 1.0-18.0,  Status Asthmaticus children, 1 years of age, with a known history of asthma admitted to the PICU at St John's Children's Hospital with status asthmaticus clinical asthma score (CAS) between 3 after receiving one dose of systemic steroid, 1 hour of continuous albuterol (SABA), and 3 doses of ipratropium bromide written informed consent from the patient's parent or legal guardian  no previous history of asthma absence of airway protective reflexes absence of respiratory drive excessive oral secretions need for emergent intubation as determined by the attending physician facial or airway anomaly or injury precluding the use of tight fitting mask
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 10.0-80.0,  Asthma Current non-smoking (<10 pack yr smoking history) Stable, treated asthmatics Age 10-80 yr post 180ug albuterol by MDI: FEV 1/FVC < 70% and FEV 1 <80% predicted  Pregnancy
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 20.0-70.0,  Persistent Asthma Patient Patient aged 20-70 years Patient diagnosed with asthma over six months ago Asthma diagnosis Airway reversibility, FEV1 ≥ 12% and 200mL or Airway hyper-responsiveness, PC20 < 16 mg/mL or More than two weeks, more than 2 times a day in excess of 20% PEFR diurnal variability patient FEV1 55-100% of predicted value patient Inhaled corticosteroids alone or inhaled corticosteroids and beta agonists used patient Currently, at least if you have one or more asthma symptoms, asthma control test (ACT • Asthma Control Test) score of less than 19 characters Patients who sufficiently listen to the purpose and content of this trial and the properties of investigational products and voluntarily agree with the participation to sign a written consent approved by IRB of Ajou University Medical Center before the participation in this trial  Current smoking or smoking in the past 15packyears Patients who show a symptom of an acute disease within 14 days before the beginning of this trial (administration of trial medication) Recent changes in asthma treatment for 28days Chronic diseases that affect the quality of life
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-16.0,  Asthma Exacerbation patients aged 2 to 16 years acute asthma exacerbation requiring an oral corticosteroid (either prednisone or prednisolone) any "reactive airways disease" treated like asthma [Asthma is defined as at least 2 wheezing episodes and/or the patient has been treated with beta agonist and/or inhaled, oral or intravenous corticosteroids for the recurrent episodes of wheezing in the past] [Acute asthma exacerbation is defined as wheezing episode with any of the following symptoms: tachypnea, dyspnea, use of accessory muscles, or an increased need for short acting beta agonist prior to presentation to PED]  any systemic corticosteroid use within 1 week of presentation to PED use of any other corticosteroid apart from oral prednisone or prednisolone for the current acute asthma exacerbation bronchiolitis underlying chronic medical condition other than asthma (ie: cystic fibrosis, nephrotic syndrome, epilepsy, etc) liver impairment (including elevated transaminases) renal impairment primary or secondary immunodeficiences concomitant immunosuppressive medication use IVIG use within 4 weeks need for assisted ventilation
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Respiratory Failure Need for non-invasive or invasive mechanical ventilation for more than 24 hours in the first 48 hours of admission to the intensive care unit  Tracheostomized patients Patients admitted to ICUs for monitoring or in post-operatory of non-complicated surgeries Patients with cancer on terminal stage
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Asthma Pulmonary Disease, Chronic Obstructive Age: for Part 1, healthy: 18 and 55 years; for Part 1, asthma: 18 and 70 years; for Part 2, nonsmokers: 40 and 65 years; for Part 2, smokers: 40 and 65 years; for Part 2, chronic obstructive pulmonary disease (COPD): 40 and 65 years Having mild, moderate, or severe asthma (for Part 1, asthma) Clinically stable asthma and have been on their current asthma controller therapy for at least 6 weeks prior to screening (for Part 1, asthma) No history of chronic respiratory disease including asthma (for Part 2, nonsmokers) Be a nonsmoker for 1 year or more at initial screening visit and have 10 packs or less per year history of smoking (for all Part 1 and Pat 2, nonsmokers) Be a current smoker with a current history of at least 20 pack years (for Part 2, smokers) Stable COPD in the 3 months prior to screening (for Part 2, COPD) Treating with Beta-adrenergic receptor agonist, anticholinergic bronchodilators, inhaled corticosteroid at stable doses for at least 4 weeks prior to screening (for Part 2, COPD)  History of sleep apnea requiring medical intervention and positive urine pregnancy screening result (for all Part 1 and Part 2) Positive urine screen for nicotine; positive serology test for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen, or hepatitis C virus antibody at screening (for all Part 1 and Part 2) Allergic bronchopulmonary aspergillosis, allergic bronchopulmonary mycosis, or occupational asthma (for Part 1, asthma) Requires long term oxygen therapy on a daily basis for chronic hypoxemia at screening visit except when used for exercise only (for Part 2, COPD) Pneumonia, COPD exacerbation that required systemic steroids, upper or lower respiratory tract infection, lung cancer surgery, lung volume reduction, or a lung transplant (for Part 2, COPD)
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-80.0,  Asthma Aged: 5-80 years Paediatric cohort (aged 5-11 years), and Adult cohort (aged 12-60 years) Non-smokers aged 61-80 years Evidence of asthma a diagnostic code for asthma, (ICD 9 codes: 493xx) or ≥2 prescriptions for asthma at different points at any time Be on current asthma therapy ≥1 other asthma prescription during the outcome period Have at least one year of baseline data (prior to the IPD) and at least one year of outcome data (following the IPD)  had been diagnosed with any chronic respiratory disease at any time other than asthma received maintenance oral steroid therapy during baseline. Updated used in the latest analysis Aged 12-60 years (paediatrics included in original study removed to make comparable with USA data) Evidence of asthma: a diagnostic code of asthma or ≥2 scripts for asthma in baseline year at different points in time Have definite dosing instructions Have at least 1 year of up-to-standard (UTS) baseline data before IPD Have at least 1 year of UTS outcome data after IPD. Index dates from 1998 onwards were accepted in the study. Updated used in the latest analysis
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-75.0,  Eosinophilic Asthma Written informed consent is obtained Patient must have completed treatment in a previous Cephalon-sponsored double-blind asthma exacerbation study or received at least 2 doses of study drug treatment in a pulmonary function study The patient must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period, and willing to return to the clinic for the follow-up evaluation as specified in this protocol other may apply; please contact the investigator for more information  The patient has a clinically meaningful comorbidity that would interfere with the study schedule or procedures, or compromise the patient's safety The patient has another confounding underlying lung disorder (eg, chronic obstructive pulmonary disease, pulmonary fibrosis, or lung cancer) The patient is a current smoker The patient is expected to be poorly compliant with study drug administration, study procedures, or visits The patient has any aggravating factors that are inadequately controlled (e.g., gastroesophageal reflux disease [GERD]) Female patients who are pregnant, or nursing, or, if of childbearing potential and not using a medically accepted, effective method of birth control (eg, spermicide, abstinence, intrauterine device [IUD], or steroidal contraceptive [oral, transdermal, implanted, and injected] in conjunction with a barrier method) are excluded from this study The patient has a current infection or disease that may preclude assessment of asthma other may apply; please contact the investigator for more information
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Respiratory Symptoms Males and females Age between 18 and 75 years old New outpatients with respiratory symptoms as dyspnoea, cough, sputum, but without firm diagnosis Results of the tests are available and acceptable Standardized list of complaints Capability of patient for doing pulmonary function tests Seen by a Pneumologist Written informed consent  Patients with diagnosed respiratory disease Younger than 18 and older than 75 years old Recent heart attack Pneumothorax hemoptoic Suspicion of Tuberculosis Not capable to do pulmonary function tests
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Severe Sepsis Clinical diagnosis of Sepsis Mechanical ventilation due to acute pulmonary dysfunction One additional (second) acute sepsis-related organ dysfunction  Pregnant women and nursing mothers Conditions or medications associated with an increased risk of bleeding/complications from anticoagulation Previous episode of sepsis during this hospitalization PaO2/FiO2 ratio < 300 Severe granulocytopenia (leukocytes <500 / μl) Acute hepatic diseases or severe liver failure or cirrhosis Chronic cardiovascular disease precluding extracorporeal treatment Human immunodeficiency virus complicated by AIDS defining illness Evidence of active bleeding uncontrolled hemorrhage
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-65.0,  Asthma Subjects with asthma as determined by ICD-9 codes and asthma drug use at least 12 years of age treated with inhaled corticosteroids  Subjects with COPD or treatment for COPD
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 6.0-15.0,  Asthma Patients with uncontrolled asthma diagnosis Patients with only one controller medication  Patients without lung infection Patients without antibiotic use
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Smokers current and regular smoker bronchoscopy under local anesthesia  patients needing EBUS or fluoroscopy intravenous sedative
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 4.0-999.0,  Asthma Subjects with asthma as determined by ICD-9 codes and asthma drug use at least 4 years of age use of at least 1 controller or at least 5 albuterol prescriptions in 12 months  Subjects with COPD or treatment for COPD
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Asthma Subjects with asthma as determined by ICD-9 codes and asthma drug use at least 65 years of age prescription for an inhaled corticosteroid  a diagnosis of chronic obstructive pulmonary disease or a prescription for a chronic obstructive pulmonary disease treatment
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 13.0-999.0,  Genetic Disease Communication Parents/Caregivers Parent or caregiver of child with DMD and child without DMD Lives with child that does not have DMD or older Reads/Writes English Siblings Sibling of child with DMD Lives in same household as individual with DMD 18 years of age Reads/Writes English